PMC:6909918 / 8527-9742 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6909918","sourcedb":"PMC","sourceid":"6909918","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6909918","text":"The available data from the included studies were extracted independently by two investigators (Chen and Peng), with any differences resolved by consensus between the two reviewers. The essential information extracted from the enrolled studies included the names of the trials, the number of patients, gender, median age, racial distribution, the Eastern Cooperative Oncology Group (ECOG) performance status, the primary site of the tumor, the KRAS status, previous treatment, and whether the patient received anti-EGFR or anti-VEGFR treatment. The length of follow-up and the duration of drug exposure were also identified. The primary outcomes evaluated in the network meta-analysis were PFS (randomized to death, regardless of cause) and OS (randomized to progression to death, regardless of cause). Secondary endpoints included ORR, with patients evaluated as partial response (PR) or complete response (CR) according to the response evaluation criteria in solid tumors (RECIST) criteria version 1.1, DCR, with patients evaluated as PR or CR or stable disease (SD) according to RECIST version 1.1, AEs of any grade, including high grade (≥grade 3) serious adverse events (SAEs), and fatal adverse events (FAEs).","tracks":[]}